Matthew Kadatz

Matthew Kadatz

Auto-generated profile, based on publicly available information

Matthew Kadatz

Department of Medicine, University of British Columbia, Vancouver, BC, Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2019 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
SCStephanie R Clark
Stephanie R Clark
MKMatthew Kadatz
Matthew Kadatz
JGJagbir Gill
Jagbir Gill
JGJohn S. Gill
John S. Gill
Background and objectives: Patients who have failed a transplant are at increased risk of repeat transplant failure. We determined access to transplantation and transplant outcomes in patients with and without a history of transplant failure. Design, setting, participants, & measurements: In this observational study of national data, the proportion of waitlisted patients and deceased donor transplant recipients with transplant failure was determined before and after the new kidney allocation system. Among patients initiating maintenance dialysis between May 1995 and December 2014, the likelihood of deceased donor transplantation was determined in patients with (n=27,459) and without (n=1,426,677) a history of transplant failure. Among transplant recipients, allograft survival, the duration of additional kidney replacement therapy required within 10 years of transplantation, and the association of transplantation versus dialysis with mortality was determined in patients with and without a history of transplant failure. Results: The proportion of waitlist candidates (mean 14%) and transplant recipients (mean 12%) with transplant failure did not increase after the new kidney allocation system. Among patients initiating maintenance dialysis, transplant-failure patients had a higher likelihood of transplantation (hazard ratio [HR], 1.16; 95% confidence interval [95% CI], 1.12 to 1.20; P<0.001). Among transplant recipients, transplant-failure patients had a higher likelihood of death-censored transplant failure (HR, 1.44; 95% CI, 1.34 to 1.54; P<0.001) and a greater need for additional kidney replacement therapy required within 10 years after transplantation (mean, 9.0; 95% CI, 5.4 to 12.6 versus mean, 2.1; 95% CI, 1.5 to 2.7 months). The association of transplantation versus dialysis with mortality was clinically similar in waitlisted patients with (HR, 0.32; 95% CI, 0.29 to 0.35; P<0.001) and without transplant failure (HR, 0.40; 95% CI, 0.39 to 0.41; P<0.001). Conclusions: Transplant-failure patients initiating maintenance dialysis have a higher likelihood of transplantation than transplant-naïve patients. Despite inferior death-censored transplant survival, transplantation was associated with a similar reduction in the risk of death compared with treatment with dialysis in patients with and without a prior history of transplant failure.

23 May 2018 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
MKMatthew Kadatz
Matthew Kadatz
SKScott Klarenbach
Scott Klarenbach
JGJagbir Gill
Jagbir Gill
JGJohn S. Gill
John S. Gill
Kidneys from deceased donors that are hepatitis C (HCV) nucleic acid test (NAT) positive are infrequently used for transplantation in HCV negative patients due to concerns of disease transmission. With the development of direct acting antivirals (DAA's) for HCV, there is now potential to use these kidneys in HCV negative candidates. However, the high cost of DAAs poses a challenge to adoption of this strategy. We created a Markov model to examine the cost‐effectiveness of using deceased donors infected with HCV for kidney transplantation in uninfected waitlist candidates. In the primary analysis this strategy was cost saving and improved health outcomes compared to remaining on the waitlist for an additional two or more years to receive a HCV negative transplant. The strategy was also cost‐effective with an incremental cost‐effectiveness ratio of $56018 per quality adjusted life year (QALY) from the payer perspective, and $4647 per QALY from the societal perspective, compared to remaining on the waitlist for one additional year. The results were consistent in one way and probabilistic sensitivity analyses. We conclude that the use of kidneys from deceased donors with HCV infection are likely to lead to improved clinical outcomes at reduced cost for HCV negative transplant candidates.

25 January 2021 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
JLJames H. Lan
James H. Lan
MKMatthew Kadatz
Matthew Kadatz
DCDoris T. Chang
Doris T. Chang
JGJagbir Gill
Jagbir Gill
HGHoward M. Gebel
Howard M. Gebel
JGJohn S. Gill
John S. Gill
Background and objectives: Panel reactive antibody informs the likelihood of finding an HLA-compatible donor for transplant candidates, but has historically been associated with acute rejection and allograft survival because testing methods could not exclude the presence of concomitant donor-specific antibodies. Despite new methods to exclude donor-specific antibodies, panel reactive antibody continues to be used to determine the choice of induction and maintenance immunosuppression. The study objective was to determine the clinical relevance of panel reactive antibody in the absence of donor-specific antibodies. Design, setting, participants, & measurements: Retrospective observational study of kidney allograft survival among 4058 zero HLA-A–, B-, DR-, and DQB1-mismatched transplant recipients without antibodies to donor kidney antigens encoded by these HLA gene loci. Results: Among 4058 first and repeat transplant recipients, patients with calculated panel reactive antibody (cPRA) 1%–97% were not at higher risk of transplant failure, compared with patients with cPRA of 0% (death censored graft loss: hazard ratio, 1.07; 95% confidence interval, 0.82 to 1.41). Patients with cPRA ≥98% had a higher risk of graft loss from any cause including death (hazard ratio, 1.39; 95% confidence interval, 1.08 to 1.79) and death censored allograft failure (hazard ratio, 1.78; 95% confidence interval, 1.27 to 2.49). In stratified analyses, the higher risk of graft loss among patients with cPRA ≥98% was only observed among repeat, but not first, transplant recipients. In subgroup analysis, there was no association between cPRA and graft loss among living related transplant recipients. Conclusions: Calculated panel reactive antibody is poorly associated with post-transplant immune reactivity to the allograft in the absence of donor-specific antibody. Podcast: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2021_01_25_CJN13640820_final.mp3

17 August 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
LGLoren Gragert
Loren Gragert
MKMatthew Kadatz
Matthew Kadatz
JAJames Alcorn
James Alcorn
DSDarren Stewart
Darren Stewart
DCDoris Chang
Doris Chang
JLJames H. Lan
James H. Lan
Implementation of the kidney allocation system in 2014 greatly reduced access disparity due to human leukocyte antigen (HLA) sensitization. To address persistent disparity related to candidate ABO blood groups, herein we propose a novel metric termed “ABO‐adjusted cPRA,” which simultaneously considers the impact of candidate HLA and ABO sensitization on the same scale. An ethnic‐weighted ABO‐adjusted cPRA value was computed for 190 467 candidates on the kidney waitlist by combining candidate's conventional HLA cPRA with the remaining fraction of HLA‐compatible donors that are ABO‐incompatible. Consideration of ABO sensitization resulted in higher ABO‐adjusted cPRA relative to conventional cPRA by HLA alone, except for AB candidates since they are not ABO‐sensitized. Within cPRA Point Group = 99%, 43% of the candidates moved up to ABO‐adjusted cPRA Point Group = 100%, though this proportion varied substantially by candidate blood group. Nearly all O and most B candidates would have elevated ABO‐adjusted cPRA values above this policy threshold for allocation priority, but relatively few A candidates displayed this shift. Overall, ABO‐adjusted cPRA more accurately measures the proportion of immune‐compatible donors compared with conventional HLA cPRA, especially for highly sensitized candidates. Implementation of this novel metric could enable the development of allocation policies permitting more ABO‐compatible transplants without compromising equity.

15 April 2024 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
MKMatthew Kadatz
Matthew Kadatz
SKScott Klarenbach
Scott Klarenbach
HSHelen So
Helen So
FFFernando C Fervenza
Fernando C Fervenza
DCDaniel C Cattran
Daniel C Cattran
SBSean J Barbour
Sean J Barbour
Background and hypothesis: The MENTOR trial (MEmbranous Nephropathy Trial Of Rituximab) showed that rituximab was noninferior to cyclosporine in inducing complete or partial remission of proteinuria and was superior in maintaining proteinuria remission. However, the cost of rituximab may prohibit first-line use for some patients and health-care payers. Methods: A Markov model was used to determine the incremental cost-effectiveness ratio (ICER) of rituximab compared with cyclosporine for the treatment membranous nephropathy from the perspective of a health-care payer with a lifetime time horizon. The model was informed by data from the MENTOR trial where possible; additional parameters including cost and utility inputs were obtained from the literature. Sensitivity analyses were performed to evaluate the impact of reduced-cost biosimilar rituximab. Results: Rituximab for the treatment of membranous nephropathy was cost effective (assuming a willingness-to-pay threshold of $50 000 per quality-adjusted life year (QALY) gained; in $US 2021) compared with cyclosporine, with an ICER of $8373/QALY over a lifetime time horizon. The incremental cost of rituximab therapy was $28 007 with an additional 3.34 QALYs compared with cyclosporine. Lower cost of rituximab biosimilars resulted in a more favorable ICER, and in some cases resulted in rituximab being dominant (lower cost and great benefit) compared to cyclosporine. Conclusions: Despite the greater cost of rituximab, it may be a cost-effective option for the treatment of membranous nephropathy when compared with cyclosporine. The cost-effectiveness of rituximab is further improved with the use of less expensive biosimilars.

7 April 2023 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
MKMatthew J. Kadatz
Matthew J. Kadatz
JGJagbir Gill
Jagbir Gill
JGJustin Gill
Justin Gill
JLJames H. Lan
James H. Lan
LMLachlan C. McMichael
Lachlan C. McMichael
JGJohn S. Gill
John S. Gill
Background: The Kidney Donor Profile Index (KDPI) is a percentile score summarizing the likelihood of allograft failure: A KDPI ≥85% is associated with shorter allograft survival, and 50% of these donated kidneys are not currently used for transplantation. Preemptive transplantation (transplantation without prior maintenance dialysis) is associated with longer allograft survival than transplantation after dialysis; however, it is unknown whether this benefit extends to high-KDPI transplants. The objective of this analysis was to determine whether the benefit of preemptive transplantation extends to recipients of transplants with a KDPI ≥85%. Methods: This retrospective cohort study compared the post-transplant outcomes of preemptive and nonpreemptive deceased donor kidney transplants using data from the Scientific Registry of Transplant Recipients. 120,091 patients who received their first, kidney-only transplant between January 1, 2005, and December 31, 2017, were studied, including 23,211 with KDPI ≥85%. Of this cohort, 12,331 patients received a transplant preemptively. Time-to-event models for the outcomes of allograft loss from any cause, death-censored graft loss, and death with a functioning transplant were performed. Results: Compared with recipients of nonpreemptive transplants with a KDPI of 0%–20% as the reference group, the risk of allograft loss from any cause in recipients of a preemptive transplant with KDPI ≥85% (hazard ratio [HR], 1.51; 95% confidence interval [CI], 1.39 to 1.64) was lower than that in recipients of nonpreemptive transplant with a KDPI ≥85% (HR, 2.39; 95% CI, 2.21 to 2.58) and similar to that of recipients of a nonpreemptive transplant with a KDPI of 51%–84% (HR, 1.61; 95% CI, 1.52 to 1.70). Conclusions: Preemptive transplantation is associated with a lower risk of allograft failure, irrespective of KDPI, and preemptive transplants with KDPI ≥85% have comparable outcomes with nonpreemptive transplants with KDPI 51%–84%.